September Is Ovarian Cancer Awareness Month: Why Canadians Need to Pay Attention

The numbers explain the urgency. An estimated 3,000 women in Canada will be diagnosed with ovarian cancer in 2026, and an estimated 1,950 will die from it. That means for every three Canadian women diagnosed this year, roughly two will not survive — a mortality ratio far worse than most other cancers affecting women. Ovarian cancer remains the most lethal gynecological cancer in the country, and outcomes for patients have barely moved in fifty years.

Why Ovarian Cancer Is So Hard to Catch Early.

Part of the problem is biological. There is no reliable screening test for ovarian cancer — no equivalent of a mammogram or a Pap test. Blood tests and ultrasounds have been studied extensively as potential screening tools, but none have been shown to improve overall survival when used on the general population. That leaves symptom recognition as the primary line of defense, and ovarian cancer’s early symptoms are notoriously easy to dismiss.

Bloating, pelvic or abdominal pain, and changes in bowel or bladder habits are among the most common signs. On their own, each of these could be explained by something as ordinary as diet, stress, or aging. The disease tends to be diagnosed late, often only after fluid begins building up in the abdomen associated with more advanced stage disease. The Society of Obstetricians and Gynecologists of Canada notes that this fluid buildup, known as ascites, can bring on bloating, distension, and shortness of breath, but by the time it appears, the cancer has frequently progressed significantly.

That is precisely the message Ovarian Cancer Canada tries to drive home every September: persistent, frequent, or worsening symptoms — ones that are unusual for you — deserve a conversation with a doctor, not a wait-and-see approach. The organization’s Patient Partner in Research program has featured survivors like Donna Peppin, who has said that until a reliable test exists, women’s own knowledge of their bodies remains their best defence.

A Canadian Story, With Canadian Gaps.

Ovarian cancer’s toll on Canadian women isn’t evenly distributed or fully understood. Five-year net survival in Canada sits at roughly 44 percent, meaning fewer than half of women diagnosed will live five years past their diagnosis. Survival is significantly better for women diagnosed before age 45 than for those diagnosed later in life, and outcomes have improved only modestly over the past several decades compared to gains made against other cancers.

There are also real gaps in Canadian data. Statistics Canada acknowledges that detailed survival information broken down by cancer stage and type isn’t consistently available at the national level, meaning researchers often have to rely on data from other countries, such as the United States, to understand how outcomes vary by how advanced the cancer is at diagnosis. That data gap is itself part of the advocacy conversation this September: better tracking could mean better-targeted care.

The pressure for change reached the political stage this summer. At the Canadian premiers’ summit in Charlottetown in July 2026, ovarian cancer patients and oncologists called on provincial leaders to improve access to treatment and diagnostic tools. Physicians pointed to drugs already available to patients in the United States that remain inaccessible in Canada and argued that a coordinated national push — more research funding, broader access to clinical trials, and stronger interdisciplinary care — is overdue.

What Awareness Month Actually Asks of Canadians.

Ovarian Cancer Awareness Month isn’t only about wearing teal, though the colour has become a recognizable symbol of the cause across the country. It’s an annual prompt for Canadians to learn the risk factors — family history of ovarian or breast cancer, BRCA gene mutations, increasing age, and never having been pregnant are among the most significant — and to understand that most cases still occur in women without an obvious inherited risk.

It’s also a call to action for the health system itself. Advocacy groups and clinicians are using September to press for more research dollars aimed at earlier detection, since finding effective screening remains one of the most significant unmet needs in Canadian oncology. Events like the Ovarian Cancer Walk of Hope, held annually in cities across the country, channel public participation directly into funding for that research.

For individual Canadians, the takeaway is simple even if the science isn’t: know your body, take persistent symptoms seriously, and don’t assume vague abdominal complaints are nothing. For a disease with no screening test and a five-year survival rate under 50 percent, awareness isn’t just a slogan — for many women, it may be the earliest warning system available.